Mass Spectrometry Services

Introduction: Why Tissue and CSF Bioanalysis Is the Defining Step in CNS Drug Development One of the greatest challenges in

Introduction: The Bioanalytical Complexity of ADC Programs Bioanalysis for an Antibody-Drug Conjugate Program is far from a straightforward analytical exercise.

Introduction: Why CRO Selection Is a Regulatory Decision, Not Just a Scientific One When sponsors prepare regulated bioanalytical services for

Introduction: Why Late-Phase Bioanalysis Requires a Different Approach As a clinical development program progresses into Phase II and Phase III,

Introduction: The Real Test of a Bioanalytical Method Begins After Validation Method validation confirms that a bioanalytical method performs reliably

Introduction: Why EMA vs FDA Bioanalytical Method Validation Differences Matter Understanding EMA vs FDA Bioanalytical Method Validation Differences is extremely

Introduction: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use released the ICH M10 Bioanalytical Method